NASDAQ:MLNT

Melinta Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.35
▼
$0.50
52-Week Range N/A
VolumeN/A
Average Volume713,628 shs
Market Capitalization$6.88 million
P/E RatioN/A
Dividend YieldN/A
Beta4.16

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Melinta Therapeutics logo

About Melinta Therapeutics

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Headlines

Crestone Joins Antimicrobials Working Group
Crestone Joins Antimicrobials Working Group
June 8, 2021 |  markets.businessinsider.com
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
March 15, 2021 |  businesswire.com
The Petri Dish: A $500M partnership, an M&A shake-up and biotech layoffs
The Petri Dish: A $500M partnership, an M&A shake-up and biotech layoffs
June 25, 2020 |  www.bizjournals.com
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
June 24, 2020 |  finance.yahoo.com
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta
June 22, 2020 |  www.businesswire.com
La Jolla Pharma makes unsolicited bid for Tetraphase Pharma
La Jolla Pharma makes unsolicited bid for Tetraphase Pharma
June 22, 2020 |  seekingalpha.com
Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
June 15, 2020 |  www.bloomberg.com
Melinta inks agreement for Tetraphase buy
Melinta inks agreement for Tetraphase buy
June 9, 2020 |  seekingalpha.com
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
June 9, 2020 |  finance.yahoo.com
Melinta enters the fray for Tetraphase Pharma with takeover bid
Melinta enters the fray for Tetraphase Pharma with takeover bid
May 15, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.83 out of 5 stars

Medical Sector

1230th out of 2,100 stocks

Pharmaceutical Preparations Industry

560th out of 832 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What stocks does MarketBeat like better than Melinta Therapeutics?

Wall Street analysts have given Melinta Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Melinta Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics Inc (NASDAQ:MLNT) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to the consensus estimate of $15.51 million. Melinta Therapeutics had a negative trailing twelve-month return on equity of 101.29% and a negative net margin of 393.39%.
View Melinta Therapeutics' earnings history.

When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?

Melinta Therapeutics shares reverse split on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the following people:
  • Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
  • Mr. John H. Johnson, CEO & Director (Age 61)
  • Dr. Thomas A. Steitz, Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen, Co-Founder

Who are some of Melinta Therapeutics' key competitors?

Some companies that are related to Melinta Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of MLNT's competitors.

What other stocks do shareholders of Melinta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), NVIDIA (NVDA), Novavax (NVAX) and Nabriva Therapeutics (NBRV).

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How much money does Melinta Therapeutics make?

Melinta Therapeutics has a market capitalization of $0.00 and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis.

How many employees does Melinta Therapeutics have?

Melinta Therapeutics employs 290 workers across the globe.

What is Melinta Therapeutics' official website?

The official website for Melinta Therapeutics is www.melinta.com.

Where are Melinta Therapeutics' headquarters?

Melinta Therapeutics is headquartered at 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.